— Volume V No. 2: May 2009 —

html file Article [html]     pdf file Article [pdf]     
The Anthrax Vaccine: A Dilemma for Homeland Security

COMMENTS

Chris Rempfer February 12, 2010 05:00
This is a very thorough and compelling meditation on the importance of continuous policy assessment and review. Successful strategies, applications, and policies must acknowledge the fluidity of events and scenarios within which the world we live. If new challenges produce the need for fresh analysis,
Read More >>
Login or Register to Add Comment
CHDS Comment Policy
AUTHOR:
Thomas Rempfer
Lieutenant Colonel Thomas Rempfer is a distinguished graduate of the U.S. Air Force Academy and currently serves as a graduate student with the Naval Postgraduate School’s Center for Homeland Defense and Security. He is an Air Force Command pilot, experienced in F-16s, F-117s, A-10s, and MQ-1s. His prior service included membership on the U.S. Air Force Cyberspace Task Force, as well as flight safety and operational risk management duties. LtCol Rempfer has testified twice before Congress and senior White House Office and DOD officials have enlisted his expertise regarding the anthrax vaccine issue. He may be contacted at tlrempfe@nps.edu.

ABSTRACT:
Past problems with the Department of Defense anthrax vaccine currently impact Department of Homeland Security and the Department of Health and Human Services policy. Following the 2001 anthrax letter attacks, those departments included the old anthrax vaccine in the Strategic National Stockpile. This article explores the Department of Defense’s experience with the vaccine, enumerating past safety, efficacy, regulatory, and legal problems. Public health policy alternative courses of action are suggested, including use of antibiotics and development of a new vaccine.

Read full article.

SUGGESTED CITATION:
Rempfer, Thomas. “The Anthrax Vaccine: A Dilemma for Homeland Security.” Homeland Security Affairs 5, issue 2 (May 2009)
http://www.hsaj.org/?article=5.2.3
http://www.hsaj.org/